Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Robert Frank Cornell, MD, Samuel Z. Goldhaber, MD, Brian G Engelhardt, MD, Javid Moslehi, MD, Madan Jagasia, MD MS, Daryl Patton, Shelton Lacy Harrell, MSN, Robert L Hall, MSN, Houston Wyatt, PharmD, Gregory Piazza, MD

Blood (2018) 132 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2018-99-112577

Published: 2018

Journal Articles

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Alexander T Cohen, MBBS MSc MD, Rim Halaby, MD, Serge Korjian, MD, Yazan Daaboul, MD, Donald Szlosek, Douglas Arbetter, MPH, Samuel Z. Goldhaber, MD, Russell Hull, MBBS, Adrian Hernandez, MD, Alexander Gold, MD, Brian Wiens, PhD, Robert Harrington, MD, C. Michael Gibson, MD

Blood (2016) 128 (22): 3824.

https://doi.org/10.1182/blood.V128.22.3824.3824

Published: 2016

Journal Articles

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Sebastian Schellong, MD, Henry Eriksson, MD PhD, Samuel Z. Goldhaber, MD, Martin Feuring, MD, Stefan Hantel, PhD, Jörg Kreuzer, MD, Sam Schulman, MD PhD, Ajay K Kakkar, MB, BS, PhD

Blood (2015) 126 (23): 4730.

https://doi.org/10.1182/blood.V126.23.4730.4730

Published: 2015

Journal Articles

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Patrick Mismetti, MD PhD, Martin Feuring, MD, Stefan Hantel, PhD, Joerg Kreuzer, MD, Samuel Z. Goldhaber, MD

Blood (2014) 124 (21): 4270.

https://doi.org/10.1182/blood.V124.21.4270.4270

Published: 2014

Journal Articles

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Patrick Mismetti, MD, Martin Feuring, MD, Stefan Hantel, PhD, Joerg Kreuzer, MD, Samuel Z. Goldhaber, MD

Blood (2014) 124 (21): 594.

https://doi.org/10.1182/blood.V124.21.594.594

Published: 2014

Journal Articles

Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Samuel Z. Goldhaber, MD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Martin Feuring, MD, Jeffrey Friedman, MD, Joerg Kreuzer, MD

Blood (2014) 124 (21): 1544.

https://doi.org/10.1182/blood.V124.21.1544.1544

Published: 2014

Journal Articles

Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II

Sam Schulman, MD, PhD, Henry Eriksson, MD, PhD, Samuel Z Goldhaber, MD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Joerg Kreuzer, MD, Nuala Peter, BSc (Hons), Jeffrey Friedman, MD

Blood (2013) 122 (21): 2375.

https://doi.org/10.1182/blood.V122.21.2375.2375

Published: 2013

Journal Articles

Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Sam Schulman, MD, PhD, Henry Eriksson, MD, PhD, Samuel Z Goldhaber, MD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Martin Feuring, MD, Nuala Peter, BSc (Hons), Jeffrey Friedman, MD

Blood (2013) 122 (21): 1136.

https://doi.org/10.1182/blood.V122.21.1136.1136

Published: 2013

Journal Articles

Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Blood (2013) 122 (21): 212.

https://doi.org/10.1182/blood.V122.21.212.212

Published: 2013

Journal Articles

Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Blood (2013) 122 (21): 582.

https://doi.org/10.1182/blood.V122.21.582.582

Published: 2013

Journal Articles

Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up

Sam Schulman, MD, PhD, David Baanstra, MD, Henry Eriksson, MD, Samuel Z. Goldhaber, MD, Ajay Kakkar, MD, Clive Kearon, MD, PhD, Sebastian Schellong, MD, Jeffrey Friedman, MD

Blood (2012) 120 (21): 21.

https://doi.org/10.1182/blood.V120.21.21.21

Published: 2012

Journal Articles

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

Sam Schulman, MD, PhD, Ajay K Kakkar, MD, Sebastian M Schellong, MD, Samuel Z. Goldhaber, MD, Eriksson Henry, MD, PhD, Patrick Mismetti, MD, PhD, Anita Vedel Christiansen, MSc.Pharm., Janet Schnee, MD, Clive Kearon, MB, PhD

Blood (2011) 118 (21): 205.

https://doi.org/10.1182/blood.V118.21.205.205

Published: 2011

Journal Articles

Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.

Ajay K Kakkar, PhD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Victor F Tapson, MD, Jean-Francois Bergmann, MD, Samuel Z. Goldhaber, MD, Frederick A Anderson, Jr., PhD

Blood (2008) 112 (11): 984.

https://doi.org/10.1182/blood.V112.11.984.984

Published: 2008

Journal Articles

Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey

Ajay K Kakkar, PhD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Victor F Tapson, MD, Jean-Francois Bergmann, MD, Samuel Z. Goldhaber, MD, Frederick A Anderson, Jr., PhD

Blood (2008) 112 (11): 171.

https://doi.org/10.1182/blood.V112.11.171.171

Published: 2008

NARROW

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™

Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II

Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.

Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only